209 related articles for article (PubMed ID: 26364657)
1. Insight into the binding mode of a novel LSD1 inhibitor by molecular docking and molecular dynamics simulations.
Zhang X; Li M; Wang Y; Zhao Y
J Recept Signal Transduct Res; 2015; 35(5):363-9. PubMed ID: 26364657
[TBL] [Abstract][Full Text] [Related]
2. Identifying the novel inhibitors of lysine-specific demethylase 1 (LSD1) combining pharmacophore-based and structure-based virtual screening.
Sun XD; Zheng YC; Ma CY; Yang J; Gao QB; Yan Y; Wang ZZ; Li W; Zhao W; Liu HM; Ding L
J Biomol Struct Dyn; 2019 Oct; 37(16):4200-4214. PubMed ID: 30366512
[TBL] [Abstract][Full Text] [Related]
3. QSAR Modeling, Molecular Docking and Molecular Dynamics Simulations Studies of Lysine-Specific Demethylase 1 (LSD1) Inhibitors as Anticancer Agents.
Abdizadeh R; Heidarian E; Hadizadeh F; Abdizadeh T
Anticancer Agents Med Chem; 2021; 21(8):987-1018. PubMed ID: 32698753
[TBL] [Abstract][Full Text] [Related]
4. 3D-QSAR (CoMFA, CoMSIA), molecular docking and molecular dynamics simulations study of 6-aryl-5-cyano-pyrimidine derivatives to explore the structure requirements of LSD1 inhibitors.
Ding L; Wang ZZ; Sun XD; Yang J; Ma CY; Li W; Liu HM
Bioorg Med Chem Lett; 2017 Aug; 27(15):3521-3528. PubMed ID: 28610981
[TBL] [Abstract][Full Text] [Related]
5. Probing the binding mechanism of substituted pyridine derivatives as effective and selective lysine-specific demethylase 1 inhibitors using 3D-QSAR, molecular docking and molecular dynamics simulations.
Wang ZZ; Yang J; Sun XD; Ma CY; Gao QB; Ding L; Liu HM
J Biomol Struct Dyn; 2019 Aug; 37(13):3482-3495. PubMed ID: 30175693
[TBL] [Abstract][Full Text] [Related]
6. Identification of Novel Selective Lysine-Specific Demethylase 1 (LSD1) Inhibitors Using a Pharmacophore-Based Virtual Screening Combined with Docking.
Zhou C; Kang D; Xu Y; Zhang L; Zha X
Chem Biol Drug Des; 2015 Jun; 85(6):659-71. PubMed ID: 25346381
[TBL] [Abstract][Full Text] [Related]
7. Investigating the Binding Mode of Reversible LSD1 Inhibitors Derived from Stilbene Derivatives by 3D-QSAR, Molecular Docking, and Molecular Dynamics Simulation.
Xu Y; He Z; Yang M; Gao Y; Jin L; Wang M; Zheng Y; Lu X; Zhang S; Wang C; Zhao Z; Zhao J; Gao Q; Duan Y
Molecules; 2019 Dec; 24(24):. PubMed ID: 31817721
[TBL] [Abstract][Full Text] [Related]
8. Utilizing a structure-based virtual screening approach to discover potential LSD1 inhibitors.
Fan Z; Liu X; Wang N; Yu S; Bi C; Si Y; Ling X; Liu C; Wang J; Sun H
J Cancer Res Clin Oncol; 2024 May; 150(5):253. PubMed ID: 38748285
[TBL] [Abstract][Full Text] [Related]
9. Design, Synthesis, and In Vitro Evaluation of Novel Histone H3 Peptide-Based LSD1 Inactivators Incorporating α,α-Disubstituted Amino Acids with γ-Turn-Inducing Structures.
Ota Y; Kakizawa T; Itoh Y; Suzuki T
Molecules; 2018 May; 23(5):. PubMed ID: 29734782
[TBL] [Abstract][Full Text] [Related]
10. Intermolecular insights into allosteric inhibition of histone lysine-specific demethylase 1.
Zhang X; Sun Y; Zhang Z; Wang H; Wang J; Zhao D
Biochim Biophys Acta Gen Subj; 2021 Nov; 1865(11):129990. PubMed ID: 34390793
[TBL] [Abstract][Full Text] [Related]
11. Identification of selective and reversible LSD1 inhibitors with anti-metastasis activity by high-throughput docking.
Li L; Li R; Wang Y
Bioorg Med Chem Lett; 2019 Feb; 29(4):544-548. PubMed ID: 30611617
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment.
Duan YC; Ma YC; Qin WP; Ding LN; Zheng YC; Zhu YL; Zhai XY; Yang J; Ma CY; Guan YY
Eur J Med Chem; 2017 Nov; 140():392-402. PubMed ID: 28987602
[TBL] [Abstract][Full Text] [Related]
13. 3-(Piperidin-4-ylmethoxy)pyridine Containing Compounds Are Potent Inhibitors of Lysine Specific Demethylase 1.
Wu F; Zhou C; Yao Y; Wei L; Feng Z; Deng L; Song Y
J Med Chem; 2016 Jan; 59(1):253-263. PubMed ID: 26652247
[TBL] [Abstract][Full Text] [Related]
14. Histone H3 peptide based LSD1-selective inhibitors.
Kakizawa T; Ota Y; Itoh Y; Tsumoto H; Suzuki T
Bioorg Med Chem Lett; 2015 May; 25(9):1925-8. PubMed ID: 25827526
[TBL] [Abstract][Full Text] [Related]
15. Discovery of resveratrol derivatives as novel LSD1 inhibitors: Design, synthesis and their biological evaluation.
Duan YC; Guan YY; Zhai XY; Ding LN; Qin WP; Shen DD; Liu XQ; Sun XD; Zheng YC; Liu HM
Eur J Med Chem; 2017 Jan; 126():246-258. PubMed ID: 27888721
[TBL] [Abstract][Full Text] [Related]
16. Nonpeptidic propargylamines as inhibitors of lysine specific demethylase 1 (LSD1) with cellular activity.
Schmitt ML; Hauser AT; Carlino L; Pippel M; Schulz-Fincke J; Metzger E; Willmann D; Yiu T; Barton M; Schüle R; Sippl W; Jung M
J Med Chem; 2013 Sep; 56(18):7334-42. PubMed ID: 24007511
[TBL] [Abstract][Full Text] [Related]
17. Identification of cell-active lysine specific demethylase 1-selective inhibitors.
Ueda R; Suzuki T; Mino K; Tsumoto H; Nakagawa H; Hasegawa M; Sasaki R; Mizukami T; Miyata N
J Am Chem Soc; 2009 Dec; 131(48):17536-7. PubMed ID: 19950987
[TBL] [Abstract][Full Text] [Related]
18. Amino-carboxamide benzothiazoles as potential LSD1 hit inhibitors. Part I: Computational fragment-based drug design.
Alnabulsi S; Al-Hurani EA; Al-Shar'i NA; El-Elimat T
J Mol Graph Model; 2019 Dec; 93():107440. PubMed ID: 31494535
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of curcumin analogues as novel LSD1 inhibitors.
Wang J; Zhang X; Yan J; Li W; Jiang Q; Wang X; Zhao D; Cheng M
Bioorg Med Chem Lett; 2019 Dec; 29(23):126683. PubMed ID: 31627991
[TBL] [Abstract][Full Text] [Related]
20. Protein recognition by short peptide reversible inhibitors of the chromatin-modifying LSD1/CoREST lysine demethylase.
Tortorici M; Borrello MT; Tardugno M; Chiarelli LR; Pilotto S; Ciossani G; Vellore NA; Bailey SG; Cowan J; O'Connell M; Crabb SJ; Packham G; Mai A; Baron R; Ganesan A; Mattevi A
ACS Chem Biol; 2013 Aug; 8(8):1677-82. PubMed ID: 23721412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]